Please use this identifier to cite or link to this item:
Title: Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Authors: Lyman, Gary H
Bohlke, Kari
Khorana, Alok A
Kuderer, Nicole M
Lee, Agnes Y
Arcelus, Juan Ignacio
Balaban, Edward P
Clarke, Jeffrey M
Flowers, Christopher R
Francis, Charles W
Gates, Leigh E
Kakkar, Ajay K
Key, Nigel S
Levine, Mark N
Liebman, Howard A
Tempero, Margaret A
Wong, Sandra L
Somerfield, Mark R
Falanga, Anna
metadata.dc.contributor.authoraffiliation: [Lyman,GH] Fred Hutchinson Cancer Research Center. University of Washington, Seattle, WA. [Kuderer,NM] University of Washington, Seattle, WA. [Bohlke,K; Somerfield,MR] American Society of Clinical Oncology, Alexandria, VA. [Khorana,AA] Cleveland Clinic, Cleveland, OH. [Lee,AY] University of British Columbia, Vancouver, British Columbia. [Levine,MN] McMaster University, Hamilton, Ontario, Canada. [Arcelus,JI] , Hospital Universitario Virgen de las Nieves. University of Granada, Granada, Spain. [Balaban,EP] Cancer Care Partnership, Mount Nittany Health and Penn State Hershey Cancer Institute, State College, PA. [Clarke,JM] Duke University Medical Center, Durham. [Key,NS] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC. [Flowers,CR] Emory University School of Medicine, Atlanta, GA. [Francis,CW] James P. Wilmot Cancer Center and University of Rochester, Rochester, NY. [Gates,LE] Patient Representative, Denver, CO. [Kakkar,AK] Thrombosis Research Institute, London, United Kingdom. [Liebman,HA] University of Southern California Keck School of Medicine. Norris Comprehensive Cancer Center, Los Angeles. [Tempero,MA] , University of California San Francisco Pancreas Center, San Francisco, CA. [Wong,SL] University of Michigan, Ann Arbor, MI. [Falanga,A] Hospital Papa Giovanni XXIII, Bergamo, Italy.
Keywords: Aspirina;Fibrinolíticos;Heparina de bajo-peso-molecular;Neoplasias;Tromboembolia venosa;Anticoagulantes
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Benzoic Acids::Hydroxybenzoic Acids::Salicylic Acids::Aspirin
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Fibrin Modulating Agents::Fibrinolytic Agents
Heparin, Low-Molecular-Weight
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Diseases::Neoplasms
Medical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Embolism and Thrombosis::Thromboembolism::Venous Thromboembolism
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Anticoagulants
Issue Date: 20-Feb-2015
Publisher: American Society of Clinical Oncology
Citation: Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015; 33(6):654-6
Abstract: PURPOSE To provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized controlled trials, systematic reviews, meta-analyses, and clinical practice guidelines from November 2012 through July 2014. An update committee reviewed the identified abstracts. RESULTS Of the 53 publications identified and reviewed, none prompted a change in the 2013 recommendations. RECOMMENDATIONS Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Routine thromboprophylaxis is not recommended for patients with cancer in the outpatient setting. It may be considered for selected high-risk patients. Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive prophylaxis with either low-molecular weight heparin (LMWH) or low-dose aspirin. Patients undergoing major surgery should receive prophylaxis starting before surgery and continuing for at least 7 to 10 days. Extending prophylaxis up to 4 weeks should be considered in those undergoing major abdominal or pelvic surgery with high-risk features. LMWH is recommended for the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for long-term secondary prophylaxis (at least 6 months). Use of novel oral anticoagulants is not currently recommended for patients with malignancy and VTE because of limited data in patients with cancer. Anticoagulation should not be used to extend survival of patients with cancer in the absence of other indications. Patients with cancer should be periodically assessed for VTE risk. Oncology professionals should educate patients about the signs and symptoms of VTE.
Description: Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't;
metadata.dc.identifier.doi: 10.1200/JCO.2014.59.7351
ISSN: 1527-7755 (Online)
0732-183X (Print)
Appears in Collections:01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
Lyman_VenousThromboembolism.pdfArtículo publicado97,23 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons